REVIEW

Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists

Chris M Bacon¹, Ming-Qing Du¹ and Ahmet Dogan²

¹ Department of Pathology, University of Cambridge, Cambridge, UK
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

Correspondence to:
Correspondence to:
Professor A Dogan
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; dogan.ahmet{at}mayo.edu

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is the third most common non-Hodgkin lymphoma subtype, accounting for around 6–8% of all non-Hodgkin lymphomas in the Western hemisphere. Although MALT lymphomas are clinically indolent, the disease is typically chronic, requiring long-term clinical surveillance and, often, repeated biopsies. Pathologists thus play a central role in the diagnosis and management of these patients. The optimal diagnosis and management of a MALT lymphoma requires careful integration of morphological, immunohistochemical and molecular information, together with close cooperation with the clinician treating the patient. This review discusses recent developments in the molecular pathogenesis of MALT lymphoma and provides strategies for integrating this information into daily pathological practice.

Abbreviations: DLBCL, diffuse large B cell lymphoma; FDC, follicular dendritic cell; FISH, fluorescence in situ hybridisation; FOX, forkhead box; MALT, mucosa-associated lymphoid tissue; NF, nuclear factor; pMRD, probable minimal residual disease

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Chng, W. J., Remstein, E. D., Fonseca, R., Bergsagel, P. L., Vrana, J. A., Kurtin, P. J., Dogan, A. (2009). Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood 113: 635-645 [Abstract] [Full Text]